Clinical Trials Browser

Phase 2 × INDUSTRY × iscalimab × Clear all

NCT02565576 2021-01-05

Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis

Phase 2 Completed

44 enrolled 17 charts

Myasthenia Gravis